The Detection and Negative Reversion of Circulating Tumor Cells as Prognostic Biomarkers for Metastatic Castration-Resistant Prostate Cancer with Bone Metastases Treated by Enzalutamide

The Detection and Negative Reversion of Circulating Tumor Cells as Prognostic Biomarkers for Metastatic Castration-Resistant Prostate Cancer with Bone Metastases Treated by Enzalutamide

Enzalutamide is a second-generation androgen receptor inhibitor that increases overall survival (OS) rates in patients with metastatic castration-resistant prostate cancer (mCRPC). This study evaluates the efficacy of circulating tumor cell (CTC) status as a prognostic biomarker following enzalutami...

Full description

Bibliographic Details
Main Authors: So Nakamura, Masayoshi Nagata, Naoya Nagaya, Takeshi Ashizawa, Hisashi Hirano, Yan Lu, Hisamitsu Ide, Shigeo Horie
Format: Article
Language:English
Published: MDPI AG 2024-02-01
Series:Cancers
Subjects:
circulating tumor cells (CTCs)
enzalutamide
bone metastases
castration-resistant prostate cancer
androgen receptor signaling inhibitor
Online Access:https://www.mdpi.com/2072-6694/16/4/772

Internet

https://www.mdpi.com/2072-6694/16/4/772

Similar Items